Pedro Kourí National Institute of Tropical Medicine, Havana, Cuba.
Finlay Institute of Vaccines, Havana, Cuba.
F1000Res. 2020 Mar 31;9:221. doi: 10.12688/f1000research.22660.1. eCollection 2020.
The World Health Organization (WHO) recommends that pneumococcal conjugate vaccines (PCVs) be included in immunization programs worldwide. In China, the 7-valent pneumococcal conjugate vaccine (PREVNAR 7®) was authorized in 2008 but was not included in the national immunization programs. In 2016, PREVNAR 13®, a 13-valent pneumococcal conjugate vaccine (PCV13), was licensed for optional use in China. We will conduct a scoping review of the distribution of serotypes and antimicrobial resistance of in children aged under 5 years in China since the introduction of PCV13. We will obtain data from PubMed, the China National Knowledge Infrastructure (CNKI), and Wanfang Med Online. We will also review epidemiological data from WHO and the China Antimicrobial Surveillance Network (CHINET). Our analysis will include the condition of interest, the intervention, and the geographical region. All types of studies will be eligible for inclusion in the study database if they meet the inclusion criteria. This scoping review is intended to outline how serotypes are distributed, and it will map their antimicrobial resistance in children aged under 5 years in China. The results of this study will provide useful information on the impact of PCV13 in China.
世界卫生组织（WHO）建议在全球免疫规划中纳入肺炎球菌结合疫苗（PCV）。在中国，7 价肺炎球菌结合疫苗（PREVNAR 7®）于 2008 年获得批准，但未纳入国家免疫规划。2016 年，13 价肺炎球菌结合疫苗（PCV13）在我国获准选择性使用。我们将对 PCV13 引入中国以来，5 岁以下儿童中肺炎球菌血清型和抗生素耐药性分布进行范围综述。我们将从 PubMed、中国国家知识基础设施（CNKI）和万方医学在线获取数据。我们还将审查来自世界卫生组织和中国抗菌药物监测网络（CHINET）的流行病学数据。我们的分析将包括关注的情况、干预措施和地理区域。如果符合纳入标准，所有类型的研究都有资格纳入研究数据库。本范围综述旨在概述中国肺炎球菌血清型的分布情况，并绘制其在 5 岁以下儿童中的抗生素耐药性图谱。本研究的结果将为了解 PCV13 在我国的影响提供有用信息。
